Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference
Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on ...
TMCnet1d
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...
Aethlon Medical strengthens oncology trial with protocol updates and cost reductions
CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% compared to the same quarter ...
Benefits Pro1d
SECURE 2.0’s auto-enrollment: Driving participation in nonprofit 403(b) retirement plans
In addition, 90% of all nonprofit employees are eligible to participate in plans, a survey high, and likely expanded due to ...
appliedclinicaltrialsonline2d
Replacing Anecdotal With Empirical Evidence On Impact of DCTs
Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...